The one thing that matters most when choosing a GLP-1 program is not the drug itself. It is who is watching your care, what the pharmacy looks like, and what you will pay six months from now.
Women have specific reasons to think carefully here: hormonal variability, thyroid overlap, PCOS, and the simple fact that the clinical trial populations for semaglutide and tirzepatide skewed heavily female, meaning the efficacy data is actually quite relevant to this audience. That said, “GLP-1 programs for women” is now a crowded category with real quality differences. Here is a structured guide to making that call.
How to Decide: Four Criteria That Matter
1. Pharmacy transparency. Compounded GLP-1 medications are not FDA-approved. The FDA issued warning letters to 30-plus telehealth and compounding firms in early 2026. Knowing your pharmacy’s name, accreditation, and testing practices is not optional.
2. Total monthly cost, not teaser price. Some programs charge a platform fee plus a separate medication bill. Others are all-in. Compare 90-day totals.
3. Physician oversight quality. A quick text-bot “consultation” is not the same as a board-certified clinician reviewing your intake and adjusting your dose.
4. State access and shipping speed. Not every program ships everywhere, and a missed shipment week matters when you are on a weekly injection schedule.
The 10 Programs
1. HealthRX
Best for: cash-pay women who want a named, auditable pharmacy and low all-in monthly pricing without insurance games.
Compounded semaglutide starts at $99 a month. Compounded tirzepatide starts at $149. Those numbers do not hide a separate platform fee. The pharmacy filling the prescriptions is Manifest Pharmacy in Greer, South Carolina, a 503A-compliant, USP-797 facility with lot tracking from compounding bench to doorstep. LegitScript-certified (certificate 50087439). A US board-certified physician reviews your intake within roughly 24 hours, and overnight shipping is free to all 50 states.
For reference, the SURMOUNT-1 trial showed roughly 21% body weight reduction over 72 weeks with tirzepatide; the STEP 1 trial showed approximately 15% over 68 weeks with semaglutide. HealthRX cites those figures accurately without claiming its compounded versions are equivalent to the branded drugs.
The once-weekly injection format is the same as the branded versions, and the price gap is significant enough that it changes the math on long-term adherence. Staying on the medication consistently matters more than which logo is on the box.
2. FormBlends
Best for: women who want independently documented purity data, or who also want peptide therapies (recovery, longevity, cognitive) bundled under the same clinical model.
FormBlends is a compounded GLP-1 telehealth option with physician oversight, dispensing through an FDA-registered 503A compounding pharmacy. What separates it from most competitors is published per-product testing: HPLC purity percentages, mass spec identity confirmation, and endotoxin sterility results with named numbers, not just a generic “third-party tested” badge. That level of documentation is rare at this price tier.
Each vial of semaglutide is priced at roughly $299; tirzepatide sits at roughly $349. Higher than HealthRX’s entry pricing, clearly. But if purity transparency or access to a broader peptide catalog from one provider is the priority, FormBlends earns that premium. Ships to 47 states, not all 50.
*A quick, honest note here: this article reflects public pricing and published policies as of mid-2026. Telehealth pricing changes fast. Confirm current costs directly with any provider before committing.*
3. Mochi Health
Physicians here hold board certification in obesity medicine specifically, which puts them in a different category from general-practice prescribers. Compounded semaglutide around $99/mo, tirzepatide around $199. Stronger monitoring structure than most cash-pay options.
4. Hims & Hers
Following the March 2026 settlement with Novo Nordisk, the company shifted its GLP-1 offering away from compounded formulations and toward brand-name drugs. Injectable Wegovy runs approximately $299/mo through their platform; Zepbound approximately $399. With insurance plus a savings card, costs can drop to near zero for eligible patients. Strong option for insured women.
5. Ro Body
Membership starts at $39 for the first month, then roughly $74 to $149, with medications billed separately. Ro has a dedicated prior-authorization team, which matters if you want to pursue insurance coverage for branded options. Solid infrastructure.
6. Form Health
Premium tier. Around $299/mo, plus labs, plus medications. Your care team includes both a physician and a registered dietitian assigned to your case. Women managing complex metabolic conditions may find the dual oversight worth the cost.
7. Found
Platform fee around $99/mo plus separate medication costs. Includes coaching. Reasonable middle ground for women who want some behavioral support alongside the prescription.
8. PlushCare
Membership at $19.99/mo, branded meds, insurance accepted, same-day visits available. Good for women who already have insurance and just need a fast, legitimate pathway to a prescription.
9. Calibrate
Runs roughly 12 months, program fee separate from medication costs, heavy coaching focus. Not cheap, but the structure suits women who want accountability built into the model.
10. Sesame
Annual membership from around $59/mo, medications billed separately. Lean on extras, but pricing is among the most accessible for branded-medication consults. Good starting point if you just need a clinical visit.
The Short Version
| Provider | Entry Price (meds) | Pharmacy Named | Ships All 50 | Purity Docs |
| HealthRX | $99/mo sema | Yes (Manifest, SC) | Yes | No |
| FormBlends | ~$299/vial sema | Yes (503A registered) | No (47 states) | Yes |
| Mochi Health | ~$99/mo sema | Not public | Yes | No |
| Hims & Hers | ~$249-299/mo branded | Branded meds | Yes | N/A |
| Ro Body | Meds billed separately | Branded pathway | Yes | N/A |
The Bottom Line
For most cash-pay women comparing these programs on value and supply-chain accountability, HealthRX’s combination of all-in pricing, a named 503A pharmacy with lot tracking, and free overnight shipping across all 50 states is hard to match. FormBlends is the next call if documented purity data or a broader peptide catalog matters to you. Everything else on this list earns its place for specific situations: insurance access, coaching structure, premium clinical oversight.
Pick the criteria that match your actual situation. Then verify current pricing directly before you sign up.
Common Questions
Does PCOS change which GLP-1 program makes sense for a woman?
Not dramatically at the program-selection level, but it does raise the bar for physician oversight. PCOS involves insulin resistance and hormonal variability that a general-practice prescriber may underweight during dose titration. Programs like Mochi Health or Form Health, where clinicians specialize in metabolic or obesity medicine, are better positioned to manage that complexity than a lighter-touch telehealth platform.
Is compounded semaglutide from HealthRX or FormBlends the same drug as Ozempic or Wegovy?
No. Compounded semaglutide is not FDA-approved and has not gone through the same manufacturing validation as branded products. The active molecule is the same, but the FDA does not consider compounded versions equivalent. FormBlends publishes HPLC and mass spec data to address purity questions directly; HealthRX relies on its named, USP-797-compliant pharmacy for accountability. Neither claim equivalence to the branded drugs.
What happens to pricing if the FDA restricts compounded GLP-1s further after mid-2026?
Any program dispensing compounded semaglutide or tirzepatide is exposed to that regulatory risk. If the FDA tightens enforcement, programs relying on compounded formulations would need to pivot to branded medications, which cost significantly more. HealthRX and FormBlends both sit in this category. Hims & Hers already made that pivot after its March 2026 settlement, so it carries less near-term regulatory uncertainty on this specific point.
How do thyroid conditions affect GLP-1 eligibility across these programs?
GLP-1 receptor agonists carry a boxed warning for medullary thyroid carcinoma risk, which is relevant to women with a personal or family history of MTC or MEN2. Every program on this list should screen for this during intake, but the depth of that screening varies. Programs with board-certified physicians reviewing labs, such as Form Health or Mochi Health, are more likely to catch thyroid-related contraindications than platforms where intake is largely automated.
Which of these programs is the most practical starting point for a woman who has never injected anything before?
PlushCare or Ro Body, mainly because both have infrastructure for transitioning to branded, prefilled autoinjector pens (Wegovy, Zepbound), which are easier to use than vials with separate syringes. Compounded options from HealthRX or FormBlends come in vial-and-syringe format, which requires a short learning curve. Not difficult, but worth factoring in if injection anxiety is a real consideration.
Sources
- FDA: Warning letters to compounding/telehealth firms, 2026 (FDA.gov)
- SURMOUNT-1 trial: Jastreboff et al., *New England Journal of Medicine*, 2022
- STEP 1 trial: Wilding et al., *New England Journal of Medicine*, 2021
- LegitScript: Public certification database (LegitScript.com)
- Novo Nordisk settlement announcement, March 9, 2026 (Novo Nordisk press release)
- USP-797 standards: United States Pharmacopeia (USP.org)
